Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Raymond James Financial, Inc. — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Raymond James Financial, Inc. trades at $158.14 (market cap $30.25B). The key difference: Raymond James Financial, Inc. is far larger — about 17.7× Nuvation Bio Inc. Class A Common Stock's market cap, and Raymond James Financial, Inc. pays a 1.37% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Raymond James Financial, Inc. for 74 Days on average.
| NUVB | RJF | |
|---|---|---|
Market Cap | $1.71B | $30.25B |
Volume | 5,448,712 | 1,288,635 |
Sector | Health | Financials |
52-Week High | $9.54 | $181.18 |
52-Week Low | $3.41 | $140.89 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $1.30B | $24.12B |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Raymond James Financial (RJF) trades at $158.6, down 0.58% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.14, and maintains solid fundamentals including a P/E of 13.71 and ROE of 18.48%. Recent news highlights executive leadership changes and a declared dividend of $0.54 per share payable in October 2026.
The outlook is mixed: analyst consensus is a 'Hold' with a $184 price target, implying potential upside, but technical weakness and high investing cash outflows pose risks. Revenue growth and margin stability support long-term value, though market volatility and expense pressures remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
